Compare MARPS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MARPS | BOLT |
|---|---|---|
| Founded | 1956 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 7.3M |
| IPO Year | N/A | 2021 |
| Metric | MARPS | BOLT |
|---|---|---|
| Price | $4.74 | $3.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 6.9K | ★ 16.4K |
| Earning Date | 02-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $4.05 | $3.75 |
| 52 Week High | $6.49 | $7.20 |
| Indicator | MARPS | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 54.18 | 41.28 |
| Support Level | $4.74 | N/A |
| Resistance Level | $5.20 | $5.05 |
| Average True Range (ATR) | 0.15 | 0.25 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 50.75 | 6.94 |
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.